A股異動丨堅瑞沃能兩連板 重整計劃獲批通過
格隆匯12月31日丨堅瑞沃能(300116.SZ)兩連板,報1.96元,總市值47.68億元。

堅瑞沃能12月29日晚間發佈公告,第二次債權人會議及出資人組會議於12月27日召開,《重整計劃(草案)》、《出資人權益調整方案》均獲會議通過,同日,公司管理人向陝西省西安市中級人民法院提交了《裁定批准重整計劃的申請書》,西安中院作出了《民事裁定書》,批准公司重整計劃。喧囂近兩年的債務危機,終於迎來轉機。堅瑞沃能表示,清償債務等執行重整計劃的行為將對公司2019年度的淨利潤、2019年末的淨資產產生一定影響,具體數據以經審計的財務報表數據為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.